Hainan 2026 Medtech Series #1: The Medical Device Gateway Foreign Medtech Shouldn't Ignore
In previous articles, I explored Hainan's e-commerce. This time, I want to turn to a sector where the policy advantage is even more unique: medical devices. This is also more or less my field of expertise. For foreign medtech companies eyeing China, Hainan now offers a combination of import flexibility, clinical pathways, and manufacturing incentives that exists nowhere else in the country. I will write a series of four articles covering Hainan as a pathway for medical devices and pharmaceuticals to enter China market. This is the first one.
The Boao Lecheng advantage: use first, register later
At the heart of this story is the Boao Lecheng International Medical Tourism Pilot Zone. It permits the use of medical devices and drugs that are approved in major overseas markets (CE-marked, FDA-cleared) but not yet registered with China's NMPA (= National Medical Products Administration) — without requiring domestic clinical trials first. Patients can access the technology, and critically, the real-world clinical data generated can be used to support NMPA registration, significantly shortening the path to national market entry.
Hainan Boao Lecheng is a place to build Chinese physician familiarity and generate local evidence while the regulatory dossier is prepared. For an innovative orthopaedic implant maker or a diagnostic device startup, that's a strategic foothold they can't get in Shanghai or Beijing.
Zero tariffs and the manufacturing equation
With independent customs now operational, imported components and production equipment enter Hainan duty-free. Combine that with the 30% value-added rule, and the business case for local manufacturing sharpens: assemble or process devices in Hainan, meet the threshold, and sell into the mainland without standard import duties.
The policy toolkit in one place
For clarity, here are the core incentives relevant to foreign medical device companies:
· Duty-free import of devices and components into Hainan
· Boao Lecheng pilot allowing clinical use of unregistered overseas devices and real-world data submission to NMPA
· Manufacturing pathway into mainland market via 30% value-add rule
Why this matters now
China's medical device market is already the world's second largest. Hainan gives foreign companies a rare chance to test, gather evidence, and produce — all under a supportive tax and customs framework. In my view, the window is especially attractive for medium-sized innovators who lack the capital for a full mainland clinical trial but have CE or FDA clearance and want to prove their technology in the Chinese clinical setting.
In my next piece, I'll walk through the Boao real-world data pathway in more detail and what it takes to turn a Boao Lecheng pilot into full NMPA approval.
Author:
Ulla Nurmenniemi
Chairman, Wellbridge Ltd (Beijing & Haikou)
Vice Chairman, FinnCham China - Beijing
Submit Cancel